Date:7/14/2008

of the company's pandemic influenza vaccines. Risks and uncertainties include whether results from the Phase 1 trial will be favorable; whether Vical or others will continue development of the pandemic influenza vaccines or any other product candidates; whether results from the Phase 1 trial will determine next steps in the company's pandemic influenza vaccine program or expand collaborative opportunities for the Vaxfectin(R) adjuvant or the Vical DNA vaccine technology; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; the dependence of the company on its collaborative partners; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors:

Alan R. Engbring

Vical Incorporated

(858) 646-1127

aengbring@vical.com

Website: http://www.vical.com

Media:

Heidi Chokeir, Ph.D., or David Schull

Russo Partners

(619) 814-3512

heidi.chokeir@russopartnersllc.com

'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Cervical cancer screening: Too many are left unprotected
2. Couples more likely to divorce if spouse develops cervical or testicular cancer
3. Gene-Based Screen Spots Cervical Cancer Earlier
4. Transcutaneous cervical esophageal ultrasound can not substitute for 24-h pH monitoring or manometry
5. Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released
6. Study: HPV test beats Pap in detecting cervical cancer
7. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
8. Pa. Funding for Cervical Cancer Prevention Services Ends
9. Precancerous Lesions Raise Cervical Cancer Risk
10. American Medical Womens Association Supports New Bill That Requires Medicare Coverage of HPV Testing as Part of Cervical Cancer Screening
11. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment